A股異動丨艾迪藥業(688488.SH)漲6.6% 抗艾創新藥ACC008上市許可申請獲得受理
格隆匯5月20日丨艾迪藥業(688488.SH)漲6.6%,盤中高見22.88元創逾四個月新高,最新總市值92億元。艾迪藥業公吿,公司收到國家藥品監督管理局於2021年5月19日簽發的關於公司抗艾滋病領域在研1類新藥ACC008片境內生產藥品註冊上市許可申請的《受理通知書》。在研抗艾滋三聯單片複方製劑ACC008,是公司在ACC007的基礎上,聯合2個核苷類逆轉錄酶抑制劑(拉米夫定和替諾福韋)開發的國產首款三合一單片複方創新藥製劑,其組合方案及藥物選擇符合國際趨勢,於2019年12月被列入國家十三五“重大新藥創制”科技重大專項。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.